China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization (CDMO) with a business unit in Shanghai, has reportedly raised close to RMB 250 million (USD 36.7 million) in a Series B financing round. The round was led by Shanghai Biomedicine Fund and included contributions from Oriental Jiafu Asset Management, Haitong Capital, and Xinghua Dingli Private Equity Fund Management, alongside existing investors Haibang Capital and YinXinGu Capital.
Funding Details and Use of Proceeds
The proceeds from the Series B financing round will be used for team building and the construction of a 2,000-liter production line. This follows the company’s RMB 80 million (USD 11.7 million) Series A financing round closed in April last year.
Company Overview and Services
Founded in 2015, Healsun Biopharm provides a range of services including antibody druggability analysis, protein transient expression, antibody and recombinant protein Chemistry Manufacturing and Controls (CMC) development, and antibody drug conjugate development. Notably, the company was entrusted to develop Beijing Lepu Pharmaceutical Technology Co., Ltd’s glucagon-like peptide-1 receptor agonist, the first biosimilar of Eli Lilly’s Trulicity (dulaglutide) to enter clinical trials in China. Additionally, Healsun Biopharm has made six Investigational New Drug (IND) filings in China, the US, and Australia.-Fineline Info & Tech
